JPRN-UMIN000019393
Recruiting
未知
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenib - Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs
Dokkyo Medical University, Department of Urology0 sites30 target enrollmentOctober 19, 2015
ConditionsRenal cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Renal cell carcinoma
- Sponsor
- Dokkyo Medical University, Department of Urology
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Renal cell carcinoma without target lesion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Observational study on changes in renal function after new intravitreal drug administratioJPRN-UMIN000050623Others60
Recruiting
Not Applicable
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosisJPRN-UMIN000040179Hokkaido University400
Completed
Not Applicable
Changes in the factors associated with the renal prognosis during 12 months before and after administration of luseogliflozin in patients with type 2 diabetesdiabetes mellitusJPRN-UMIN000041193Department of Diabetes, Metabolism and Kidney Disease,Edogawa Hospital238
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-005033-31-FRAddmedica S.A.S
Completed
Not Applicable
Prospective evaluation of renal function and proteinuria in chronic kidney disease patientsProteinuriaJPRN-UMIN000007371Aichi welfare agricultural cooperative association Anjo Kosei Hospital60